- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00735410
Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009
A Phase III, Multicenter, Uncontrolled, Open-label Study to Evaluate Safety and Immunogenicity of Preservative Free, Inactivated Split Influenza Vaccine, Using the Strain Composition 2008/2009 When Administered to Adult and Elderly Subjects
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Hessen, Tyskland, 35033
- Site 1, 2 and 3
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- ≥ 18 years of age, mentally competent, willing and able to give informed consent prior to study entry
- available for all the visits scheduled in the study and able to comply with all study requirements
- in good health as determined by: medical history physical examination clinical judgment of the investigator
Exclusion Criteria:
- They Have any serious (in the judgment of the investigator) disease, including but not limited to:
Cancer, except for localized skin cancer Advanced congestive heart failure Chronic obstructive pulmonary disease (COPD) Autoimmune disease (including rheumatoid arthritis) Acute or progressive hepatic disease Acute or progressive renal disease Severe neurological or psychiatric disorder Severe Asthma
- They have a history of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study vaccine (e.g., to ovalbumin, chicken protein, chicken feathers, influenza viral protein neomycin or polymyxin).
- Known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) resulting for example from:
receipt of immunosuppressive therapy (any parental or oral cortical steroid or cancer chemotherapy/radiotherapy) within the past 60 days and for the full length of the study; Receipt of immunostimulants, Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within the past 3 months and for the full length of the study, Suspected or known HIV infection or HIV-related disease.
- Known or suspected history of drug or alcohol abuse.
- They have a bleeding diathesis or conditions associated with prolonged bleeding time that in the investigator's opinion would interfere with the safety of the subject;
- Women who are pregnant or woman of childbearing potential unwilling to practice acceptable contraception for the duration of the study (21 days).
- Influenza vaccination or laboratory confirmed influenza within the last 6 months and more than one influenza vaccination within the past 12 months
- Within the past 4 weeks they have received:
another vaccine any investigational agent;
- Any acute or chronic infection requiring systemic antibiotic treatment or antiviral therapy within the last 7 days.
- They have experienced fever (i.e., axillary temperature ≥ 38°C) within the last 3 days
- Simultaneous participation in another clinical study.
- Any condition, which, in the opinion of the investigator, might prevent the subject from participation or interfere with the evaluation of the study objectives.
- Severely obese with Body Mass Index (BMI) > 35
- Site personnel involved in evaluation of safety and their immediate relatives are excluded from participation.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: 1
|
1 dose of Split influenza vaccine
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Utvärdering av antikroppssvar mot varje influensavaccinantigen, mätt med hemagglutinationsinhibition (HI) test på dag 0 och dag 21
Tidsram: 21 dagar (-1/+7)
|
21 dagar (-1/+7)
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Evaluation of safety of the influenza vaccine
Tidsram: 21 days (-1/+7)
|
21 days (-1/+7)
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- V44P12S
- 2008-000887-18
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Seasonal Influenza, Vaccine
-
University of OuluAvslutadSeasonal Affective Disorder (SAD)Finland
-
GlaxoSmithKlineAvslutadSeasonal Affective Disorder (SAD)Förenta staterna, Kanada
-
University of Colorado, DenverNational Cancer Institute (NCI); University of California, Los AngelesAvslutadHPV-vaccin | Ungdomshälsa | Vaccin | Immunisering | Reproduktiv hälsa | Förebyggande hälsovård | Vaccin mot humant papilomvirus | HälsoregistretFörenta staterna
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI); University of Minnesota; Kaiser PermanenteAvslutadHPV-vaccin | Kommunikationspraxis för leverantörer | Praxis för rekommendationer av vaccinFörenta staterna
-
Tufts UniversityMerck Sharp & Dohme LLCHar inte rekryterat ännu
-
Fudan UniversityThe University of Hong KongHar inte rekryterat ännu
-
Johns Hopkins Bloomberg School of Public HealthAvslutadVaccin tveksamhetIndien
-
Dartmouth-Hitchcock Medical CenterAvslutad
-
Duke UniversityUniversity of South CarolinaAvslutad
-
University of Maryland, BaltimoreMerck Sharp & Dohme LLCAvslutadHPV-vaccinFörenta staterna
Kliniska prövningar på Seasonal Influenza Vaccine
-
ModernaTX, Inc.Aktiv, inte rekryterandeSäsongsinfluensaFörenta staterna
-
Sinovac Biotech Co., LtdAvslutad
-
William Beaumont HospitalsAvslutad
-
University of PretoriaUniversity of StellenboschAktiv, inte rekryterande
-
National Institute of Allergy and Infectious Diseases...PPDAvslutadMottagare av njurtransplantationFörenta staterna
-
Institute of Medical Biology, Chinese Academy of...Jiangsu Province Centers for Disease Control and PreventionAvslutad
-
Laval UniversityAvslutadMänskligt papillomvirusKanada
-
ANRS, Emerging Infectious DiseasesLinKinVax; Vaccine Research Institute (VRI), FranceHar inte rekryterat ännu
-
NovavaxAktiv, inte rekryterandeCovid-19 | InfluensaAustralien, Nya Zeeland
-
CMV Research FoundationInternational AIDS Vaccine InitiativeAvslutadCytomegalovirusFörenta staterna